Save time and money with
Med Tech Market Research


MedTech Business intelligence
supplied through Trade Tracker, Research and Markets and GlobalData

Abbott Laboratories: PharmaVitae Profile

Publication Date: September 2009
Publisher: Datamonitor
Pages:117

Price £5,700.00
approximately: $9,444 | €6,321

Summary

This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

  • Benchmark Abbott's performance against key rivals in the prescription pharmaceutical sector.
  • Discover how Abbott has utilised M&A to become one of the worlds largest multi-disciplinary healthcare companies.
  • Investigate the strategies being employed by Abbott to overcome an under strength pipeline and various litigation proceedings.

Contents

  • ABOUT DATAMONITOR HEALTHCARE
    • About the PharmaVitae team
  • Chapter 1 About this profile
    • PharmaVitae Explorer database
  • Chapter structure
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • Chapter 2 Executive summary
    • Key findings
    • Prescription pharmaceutical sales and growth rate performance, 2002-14
    • Financial performance, 2002-14
    • Abbott: PharmaVitae forecasts at a glance
    • Strategic insight
    • Acquisitions help dictate Abbott's growth strategy
    • Knoll Pharmaceuticals
    • Guidant's vascular division
    • Kos Pharmaceuticals
    • Advanced Medical Optics
    • Abbott can boast the number one share of the immunology and inflammation biologic space
    • Litigation proceedings intensify battle in anti-TNF space
    • Evolution of lipid management portfolio positions Abbott as a leader in the lucrative dyslipidemia market
    • Kos acquisition diversifies Abbott's lipid management portfolio further
    • New fibrate/statin combination could hold the future for Abbott's lipid management portfolio
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • Table of Contents
    • Table of figures
  • Chapter 3 Quarterly news update
    • Product developments
    • Deals and alliances
    • Product deals
    • M&A activity
    • Company announcements
    • Future product milestones
  • Chapter 4 Company introduction
    • Key findings
    • Background
    • Key corporate developments
    • M&A history
    • Knoll Pharmaceuticals
    • Guidant's vascular business
    • Kos Pharmaceuticals
    • Advanced Medical Optics
    • M&A strategy
    • Current corporate structure
  • Chapter 5 Company sales
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2002-14
    • Historical analysis
    • Forecast analysis
    • Product analysis
    • Product analysis, 2002-08
    • Growth drivers
    • Growth resistors
    • Product analysis, 2008-14
    • Growth drivers
    • Growth resistors
    • Therapy area analysis
    • Geographic analysis
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2008-14
    • Core analysis, 2008-14
    • Expiry analysis, 2008-14
    • Molecule type analysis
    • Externalization analysis
  • Chapter 6 Company financials
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
    • Operating costs and profit analysis
    • Operating costs and profit analysis, 2002-08
    • Operating cost ratio and profit margin analysis, 2002-08
    • Operating cost ratio and profit margin analysis, 2008-14
    • Operating costs and profit analysis, 2008-14
  • Chapter 7 Key products and competitors
    • Key findings
    • Overview
    • Immunology and inflammation
    • Humira
    • Overview
    • Sales forecast
    • First fully human anti-TNF alpha mAb
    • Aggressive indication broadening
    • Bolstered manufacturing capabilities
    • Humira growth outstrips rivals Enbrel and Remicade
    • Significant dosing and delivery advantages help drive uptake
    • Further growth across all indications expected, despite new launches
    • Gold standard approval for Crohn's disease drives sales growth
    • New launches set to increase autoimmune competitive threat
    • Cardiovascular
    • Fenofibrate franchise (TriCor/TRILIPIX/Certriad)
    • Overview
    • Sales forecast
    • TriCor provides foundation for Abbott dyslipidemia franchise
    • NanoCrystal reformulation strategy key to defense from generics
    • Next-generation fibrate set to replace TriCor as Abbott's leading CV drug
    • TRILIPIX/Certriad clinical development program
    • Impressive outlook for new fibrate franchise
    • Niaspan/Simcor
    • Overview
    • Sales forecast
    • Kos' lucrative nicotinic acid franchise adds significant value to Abbott
    • Abbott has secured impressive growth from Niaspan since the merger with Kos
    • Simcor could become dominant member of nicotinic acid franchise
    • Infectious diseases
    • Kaletra
    • Overview
    • Sales forecast
    • Antiviral combination drug offering high efficacy with no signs of resistance
    • Antiviral sales growth driven by combination therapies
    • Kaletra under threat from Reyataz
    • Atripla to take market share away from NRTI FDCs
    • Kaletra and Reyataz challenged by Johnson & Johnson's Prezista
    • Respiratory
    • Flutiform
    • Overview
    • Sales forecast
    • Kos purchase gives Abbott rights to potentially lucrative respiratory medication
    • Phase III trials highlight benefits of combination therapy
    • First me-too ICS/LABA combination to market
    • Oncology
    • Lupron
    • Overview
    • Sales forecast
    • TAP dissolution sees Abbott assume full commercial rights for Lupron
    • Sales strong despite rival therapeutics
    • Central nervous system
    • Depakote
    • Overview
    • Sales forecast
    • Abbott's blockbuster antiepileptic therapy is patent protected to 2008
    • Extended release formulation provides temporary insulation from generics
    • Antiepileptic market set to be transformed by blockbuster patent expiries
  • Chapter 8 Appendix
    • R&D pipeline
    • References
    • Abbreviations
    • Exchange rates
    • About Datamonitor
    • About Datamonitor Healthcare
    • Datamonitor consulting
    • Disclaimer
  • List of Tables
    • Table 1: Abbott - PharmaVitae forecasts at a glance
    • Table 2: Anti-TNF market overview
    • Table 3: Overview of Abbott's lipid management portfolio
    • Table 4: Abbott key product developments, 2009
    • Table 5: Abbott product deals and alliances, 2009
    • Table 6: Abbott M&A activity, 2009
    • Table 7: Abbott company announcements, 2009
    • Table 8: Abbott future product milestones, 2009-11
    • Table 9: Abbott product portfolio overview ($m), 2002-08
    • Table 10: Abbott product portfolio overview ($m), 2008-14
    • Table 11: Abbott prescription pharmaceutical sales by therapy area ($m), 2008-14
    • Table 12: Abbott prescription pharmaceutical sales by geographic region ($m), 2008-14
    • Table 13: Abbott launch portfolio overview ($m), 2008-14
    • Table 14: Abbott core portfolio overview ($m), 2008-14
    • Table 15: Abbott expiry portfolio overview ($m), 2008-14
    • Table 16: Abbott prescription pharmaceutical sales by molecule type ($m), 2008-14
    • Table 17: Abbott prescription pharmaceutical sales by source ($m), 2008-14
    • Table 18: Total Abbott sales by business unit ($m), 2002-08
    • Table 19: Abbott operating revenue/cost analysis ($m), 2002-08
    • Table 20: Abbott operating cost ratio analysis (% of total revenues), 2002-08
    • Table 21: Abbott operating cost ratio analysis (% of total revenues), 2008-14
    • Table 22: Abbott operating revenue/cost analysis ($m), 2008-14
    • Table 23: Key products overview
    • Table 24: Humira: overview
    • Table 25: Humira: sales forecast ($m), 2008-14
    • Table 26: Anti-TNF market overview
    • Table 27: TriCor/TRILIPIX: overview
    • Table 28: Certriad: overview
    • Table 29: TriCor/TRILIPIX: sales forecast ($m), 2008-14
    • Table 30: Certriad: sales forecast ($m), 2008-14
    • Table 31: Niaspan: overview
    • Table 32: Simcor: overview
    • Table 33: Niaspan: sales forecast ($m), 2008-14
    • Table 34: Simcor: sales forecast ($m), 2008-14
    • Table 35: Kaletra: overview
    • Table 36: Kaletra: sales forecast ($m), 2008-14
    • Table 37: Top six anti-HIV treatments, global sales ($m) 2008
    • Table 38: Flutiform: overview
    • Table 39: Flutiform: sales forecast ($m), 2008-14
    • Table 40: Lupron: overview
    • Table 41: Lupron: sales forecast ($m), 2008-14
    • Table 42: Depakote: overview
    • Table 43: Depakote: sales forecast ($m), 2008-14
    • Table 44: Top antiepileptic therapeutics, sales ($m) 2002-08
    • Table 45: Abbott's R&D pipeline (Phase I-registration)
    • Table 46: Exchange rates, 2009
  • List of Figures
    • Figure 1: The PharmaVitae Explorer
    • Figure 2: Abbott prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
    • Figure 3: Abbott's financial performance ($m), 2002-14
    • Figure 4: I&I biologic sales by company (% total market), 2002-14
    • Figure 5: Sales of Abbott's lipid management portfolio ($m), 2002-14
    • Figure 6: Abbott SWOT analysis
    • Figure 7: Current corporate structure
    • Figure 8: Abbott prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
    • Figure 9: Key product sales ($m), 2002-14
    • Figure 10: Abbott key sales growth drivers and resistors ($m), 2002-08
    • Figure 11: Abbott key sales growth drivers and resistors ($m), 2008-14
    • Figure 12: Abbott prescription pharmaceutical sales by therapy area ($m), 2002-14
    • Figure 13: Abbott prescription pharmaceutical sales by geographic region ($m), 2002-14
    • Figure 14: Abbott launch/core/expiry configuration ($m), 2008-14
    • Figure 15: Abbott prescription pharmaceutical sales by molecule type ($m), 2002-14
    • Figure 16: Abbott prescription pharmaceutical sales by source ($m), 2002-14
    • Figure 17: Abbott operating revenue/cost analysis ($m), 2002-14

 

To top